Phase II Study of Pharmacokinetic Model-Based ATG Dosing to Improve Survival through Enhanced Immune Reconstitution in Pediatric and Adult Patients Undergoing Ex Vivo CD34-Selected Allogeneic HCT (PRAISE-IR)

Autor:	Scordo, Michael, Perales, Miguel-Angel, Mauguen, Audrey, Lin, Andrew, Kunvarjee, Binni, Nguyen, Linh Khanh, Bieler, Jennifer, Pena, Maria Paes, Cho, Christina, Gyurkocza, Boglarka, Harris, Andrew C., Jakubowski, Ann A., Lin, Dr. Richard J., Papadopoulos, Esperanza B., Politikos, Ioannis, Ponce, Doris M., Shaffer, Brian C., Shah, Gunjan L., Spitzer, Barbara, Tamari, Roni, Giralt, Sergio A., Boelens, Jaap-Jan, Curran, Kevin J.
Zdroj:	In Transplantation and Cellular Therapy February 2024 30(2) Supplement:S487-S487
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect